154 related articles for article (PubMed ID: 37646670)
1. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
[TBL] [Abstract][Full Text] [Related]
2. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
[TBL] [Abstract][Full Text] [Related]
3. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
5. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI
Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786
[TBL] [Abstract][Full Text] [Related]
6. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson JS; Johnston PB; Kamdar M; Ibrahimi S; Izutsu K; Arnason J; Glass B; Mutsaers P; Lunning M; Braverman J; Liu FF; Crotta A; Montheard S; Previtali A; Guo S; Shi L; Solomon SR
Blood Adv; 2022 Dec; 6(23):5969-5979. PubMed ID: 36149968
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
10. Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K; Dodds M; Mack T; Lymp J; Dell'Aringa J; Smith J
Clin Pharmacokinet; 2021 Dec; 60(12):1621-1633. PubMed ID: 34125421
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
13. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.
Mohty R; Moreno Vanegas Y; Chavez JC; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2023 Feb; 23(2):121-126. PubMed ID: 36662602
[TBL] [Abstract][Full Text] [Related]
14. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Blood; 2023 Apr; 141(14):1675-1684. PubMed ID: 36542826
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A
Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195
[TBL] [Abstract][Full Text] [Related]
16. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
17. Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
Kharfan-Dabaja MA; Yassine F; Moustafa MA; Iqbal M; Murthy H
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):168-175. PubMed ID: 34699774
[TBL] [Abstract][Full Text] [Related]
18. Estimating the Cost per Clinical Outcome of Second-Line Liso-Cel Versus Autologous Stem Cell Transplantation in Patients with Transplantation-Intended Relapsed/Refractory Large B Cell Lymphoma.
Saeedian M; Badaracco J; Botros A; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Nov; 29(11):712.e1-712.e7. PubMed ID: 37544410
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
20. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
